Exeltis Pharmaceuticals Holding SL:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Exeltis Pharmaceuticals Holding SL - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11339
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:スペイン
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Exeltis Pharmaceuticals Holding SL (Exeltis), a subsidiary of Insud Pharma, is a developer, producer, and marketer of medicinal products and medical devices. The company provides products in the therapeutic areas including women’s health, dermatology, respiratory, central nervous system, infectious diseases, cardiology, ophthalmology, oncology, gastroenterology, and endocrinology, among others. It works in collaboration with healthcare professionals, patients, consumers, and other pharmaceutical companies, and health authorities to carry out its pharmacovigilence activities for identifying, assessing and reporting adverse reactions of marketed drugs. The company operates in France, Spain, Turkey, Switzerland, the US, among others. Exeltis is headquartered in Madrid, Spain.

Exeltis Pharmaceuticals Holding SL – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Exeltis Acquires Juste Farma Division from Juste labs 10
Licensing Agreements 11
Exeltis Enters into Licensing Agreement with Neurim Pharma 11
Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 12
D&A Pharma Enters into Licensing Agreement with Grupo JUSTE 13
Asset Transactions 14
Exeltis Acquires Juste Farma Division from Juste labs 14
Bial – Portela Acquires Business Unit from Grupo Juste 15
Acquisition 16
Exeltis Acquires Embil Pharma 16
Exeltis Acquires Althea Pharma 17
Exeltis Pharmaceuticals Holding SL – Key Competitors 18
Exeltis Pharmaceuticals Holding SL – Key Employees 19
Exeltis Pharmaceuticals Holding SL – Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Key Facts 2
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Exeltis Pharmaceuticals Holding SL, Deals By Therapy Area, 2012 to YTD 2018 8
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Exeltis Acquires Juste Farma Division from Juste labs 10
Exeltis Enters into Licensing Agreement with Neurim Pharma 11
Grupo Juste Enters into Licensing Agreement with RedHill Biopharma and IntelGenx 12
D&A Pharma Enters into Licensing Agreement with Grupo JUSTE 13
Exeltis Acquires Juste Farma Division from Juste labs 14
Bial - Portela Acquires Business Unit from Grupo Juste 15
Exeltis Acquires Embil Pharma 16
Exeltis Acquires Althea Pharma 17
Exeltis Pharmaceuticals Holding SL, Key Competitors 18
Exeltis Pharmaceuticals Holding SL, Key Employees 19
Exeltis Pharmaceuticals Holding SL, Other Locations 20
Exeltis Pharmaceuticals Holding SL, Subsidiaries 20

List of Figures
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Exeltis Pharmaceuticals Holding SL, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Exeltis Pharmaceuticals Holding SL:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • JP Elektroprivreda BiH d.d. Sarajevo (JPESR)-エネルギー分野:企業M&A・提携分析
    Summary JP Elektroprivreda BiH d.d. Sarajevo (Elektroprivreda BiH) is a utility company that generates, transmits, supplies, and trades electricity. It also exports and imports electricity, including the management of electricity system. The company generates electricity from coal and hydro sources. …
  • Euskaltel SA (EKT):企業の財務・戦略的SWOT分析
    Euskaltel SA (EKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Xylem Inc (XYL):企業の財務・戦略的SWOT分析
    Xylem Inc (XYL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • NARI Technology Development Co Ltd (600406):企業の財務・戦略的SWOT分析
    NARI Technology Development Co Ltd (600406) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key streng …
  • Compugen Ltd (CGEN):企業の財務・戦略的SWOT分析
    Summary Compugen Ltd (Compugen) is a predictive drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s immuno-oncology pipeline comprises COM701 and PVRIG; BAY 1905254, COM902 and TIGIT; and autoimmune diseases pipeline includes CGEN …
  • Astellas Pharma Inc (4503):企業の財務・戦略的SWOT分析
    Astellas Pharma Inc (4503) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Breakthru Beverage Group, LLC:企業の戦略・SWOT・財務分析
    Breakthru Beverage Group, LLC - Strategy, SWOT and Corporate Finance Report Summary Breakthru Beverage Group, LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Rada Electronic Industries Ltd.:企業の戦略・SWOT・財務分析
    Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report Summary Rada Electronic Industries Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Grupa Lotos SA (LTS):企業の財務・戦略的SWOT分析
    Grupa Lotos SA (LTS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • OpenHydro Group Limited:電力:M&Aディール及び事業提携情報
    Summary OpenHydro Group Limited (OpenHydro) a subsidiary of DCNS S.A. designs and manufactures marine turbines for generating renewable energy from tidal streams. The company offers installation and maintenance services for the construction of tidal farms using its Open-Centre Turbine technology. It …
  • APR Applied Pharma Research SA-医療機器分野:企業M&A・提携分析
    Summary APR Applied Pharma Research SA (APR) is a healthcare company which focuses on the development and licenses of healthcare products for rare therapeutic areas. The company offers consumer health products, prescription healthcare products and therapeutic products. APR’s product pipeline portfol …
  • Rockwool International AS:戦略・SWOT・企業財務分析
    Rockwool International AS - Strategy, SWOT and Corporate Finance Report Summary Rockwool International AS - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Enel Americas SA:企業の戦略・SWOT・財務情報
    Enel Americas SA - Strategy, SWOT and Corporate Finance Report Summary Enel Americas SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Sky Ltd:企業の戦略的SWOT分析
    Sky Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Vertex Pharmaceuticals Inc (VRTX)-製薬・医療分野:企業M&A・提携分析
    Summary Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of novel drugs for the treatment of serious and life-threatening diseases. The company offers Orkambi (ivacaftor/lumacaftor) and Kalydeco (ivacaftor) for the treat …
  • Ansaldo Energia SpA-エネルギー分野:企業M&A・提携分析
    Summary Ansaldo Energia S.p.A. (Ansaldo Energia), a subsidiary of CDP Equity SpA, is a power generation company and a supplier of power plant equipments and related services. It provides power plant equipments such as gas turbines, steam turbines, turbogenerators, and hydrogenerators used in fossil …
  • Flisom AG:電力:M&Aディール及び事業提携情報
    Summary Flisom AG (Flisom) is a manufacturer and distributor of solar modules that produces and commercializes flexible solar modules based on CIGS photovoltaic technologies. The company offers products such as ultralight solar modules, thin film photovoltaic solar modules, lightweight solar modules …
  • IndusInd Bank Ltd:企業のM&A・事業提携・投資動向
    IndusInd Bank Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's IndusInd Bank Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Massachusetts Eye and Ear Infirmary-製薬・医療分野:企業M&A・提携分析
    Summary Massachusetts Eye and Ear Infirmary (MEE) is a healthcare service provider that offers primary, medical and surgical care services. The hospital offers services through departments such as ophthalmology, otolaryngology and patient care services. Its patient care services include patient educ …
  • The Boston Beer Company, Inc. (SAM):企業の財務・戦略的SWOT分析
    The Boston Beer Company, Inc. (SAM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆